Keyword results: Hardman

SHG
SHG
PREMIUM CONTENT

Shanta Gold and Ariana – Director Selling…..should you follow suit?

I see that NED Robin Fryer at AIM-listed Shanta Gold (SHG) has dumped his entire holding of the company’s stock. And CEO of Ariana Resources has been cashing in on options – and selling. Should we read either as a cue to follow suit and sell?

Subscribe to ShareProphets to access Premium Content
AVO
AVO
PREMIUM CONTENT

Advanced Oncotherapy – Fundraise at 30p (apparently a 13% discount). Tell the truth!

AIM-listed Advanced Oncotherapy (AVO) has announced a fundraise at 30p to raise £7.7 million (before expenses) – as predicted HERE by yours truly. Time for another glass of Ouzo, methinks.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Haydale – jam tomorrow but what about cash today? This is a plain & simple ramp

AIM-listed Haydale (HAYD) has announced an initial four-year distributer agreement with Dalian Yibang Technology Co Ltd (DLYB) offering exclusive distributer rights to market Haydale’s electrically conductive graphene-enhanced masterbatch in China and Taiwan. All well and good – and it does indeed appear to be good news – but for all the jam tomorrow, what about cash today?

Subscribe to ShareProphets to access Premium Content
AVO
AVO
PREMIUM CONTENT

Advanced Oncotherapy – classy polishing of a t***?

AIM-listed jam-tomorrow cancer treatment purveyor Advanced Oncotherapy (AVO) announced yesterday that it had signed up The London Clinic to run its Harley Street clinic proton therapy centre which is under construction. Well, sort of: the deal had reached a Memorandum of Understanding. This is course good news – except that it had already signed up Circle Health to run operations, and I fancy the real reason for yesterday’s RNS was revealed in CEO Nicholas Serandour’s comment where he reveals that the previous deal with Circle Health has lapsed. I wonder when Circle walked……

Subscribe to ShareProphets to access Premium Content
AVO
AVO
PREMIUM CONTENT

Advanced Oncotherapy – fundraise via equity and debt ( bit more needed by Christmas, headline misleads)

AIM-listed Advanced Oncotherapy (AVO) announced a fundraise on Wednesday – great news! Or is it? I wonder how much cash it will actually have when all the money comes in – and why, AFTER the fundraise, did researcher-for-hire Hardman produce a report telling us all what a bargain the company is? Then there are loan and outstanding salary conversions and the total – £18.4 million – is still short of a year’s spending, and won’t all arrive until the end of September. It looks a bit desperate – especially when the loan to top up the equity raise will cost up to 15% a year in interest.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Haydale – ouzo on the way and Proactive should be ashamed; still a screaming sell

Well here we are: I’ve  been saying for months that AIM-listed Haydale (HAYD) had to raise cash in a material way, all the way down from 78p last June and now we have word of a placing at just 5p which Steve Moore published yesterday. Amazingly, even after the company more-or-less confirmed our story (or failed to deny) the shares still sit at 12.25p, having been as low as 9.75p. Some people simply won’t be told. But Proactive should be shame-faced.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Yourgene – debt cleared this is an amazing deal: STRONG BUY (plus comment on Hardman)

Companies often describe deals as “transformational” without any real justification. Yesterday’s deal by Yourgene (YGEN) really is a game changer and is fantastic news for we loyal shareholders.

Subscribe to ShareProphets to access Premium Content

Haydale – after yesterday’s selling news, yet another RNS Reach

I see that AIM-listed Haydale (HAYD) has released yet another RNS Reach to tell of an eighteen month supply agreement. The shares have jumped once again, by 12%, But, of course, it is an RNS Reach and thus should be viewed as a marketing, rather than anything significant such as mega-earnings.

Haydale – another insti bailing and more insider dealing

AIM-listed Haydale (HAYD) is still seeing its management selling shares and another institution seems to be bailing out. Of course, we know that Haydale needs a placing and it is only a matter of time before the £3.2 million black hole in the balance sheet as predicted by paid-for researcher Hardman (so I’ll bet it is more) has to be addressed.

Haydale – more insider selling tells you all you need to know

It was announced on Friday that the former CEO and now former board member of AIM-listed Haydale (HAYD) has been selling shares. Back in December it was his two colleagues at Haydale Ceramic Technologies dumping shares (over £110,000 worth). In September, former boss Ray Gibbs sold about 38,000 bits of confetti and now he’s sold a further 80,000 shares. That’s a fair bit of selling by insiders!

Haydale – well ho ho ho, time for an ouzo!

And so, at long last, AIM-listed graphene play Haydale (HAYD) has raised some money. With the shares closing at 25.5p last night, it raised just £250,000 in a placing at 20p (a 21.5% discount) and £750,000 by way of a loan from the Development Bank of Wales at 11%. Oh, and we have a new finance director (did he jump or was he pushed), the former CEO (who stepped down on the profit warning back in June) is off (did he jump or was he pushed too?) and so is a NED. 

Haydale – paid-for researcher Hardman issues another (suicide) note

As covered here on ShareProphets many times, AIM-listed Haydale (HAYD) is in deep trouble as finally admitted last Friday. I’ve been saying sell all the way down from 78p in June of this year and the shares plunged to just 13.5p on Friday – after the company warned it was short of cash and offered, effectively, yet another profit warning (the third in three months). Last night the shares were 12.25p and Hardman, which ramped the shares after hours in September only to see the shares fall in response the next day, has had another go. It is laughable.

Haydale – ramped after hours by Hardman, it didn’t work…..SELL

Yesterday at 5.20pm – no-one-is-watching o’clock – paid-for research house put out some piffle about AIM-listed Haydale (HAYD). The shares are attractively valued compared with their peer group, on P/NAV and EV/sales, and also on a DCF basis don’cha know. Well, maybe – apart from the fact it is loss-making, going to run out of cash and the last placing was at a 32% discount! If the company thought that would get a lift in the share price, I’ve got bad news….

Crime-Scene

The issue is not ramping but disclosure

The issue of disclosure of holdings and conflicts of interest by those giving investment advice is currently a live topic in the industry. At heart, writing about a stock and disseminating one’s ideas is, I would posit, for many retail investors who have been pushed even further down the pecking order post Mifid 2 and the lock out on their receiving much research, a welcome activity. Information is what feeds stock prices and what prompts investors to act. Without info everybody including the companies are worse off. 

SCE
SCE

Surface Transforms – “pleased to announce” result of open offer excess. Hmmm…

With its shares having been above 20p at the start of 2017 and still above 19p in June as it attempted to mitigate “we continue to look forward with confidence”, Surface Transforms (SCE) has announced the final result of a fundraising which it has emphasised has seen a “most encouraging response from shareholders”. At what price per share again?...

Chocolate-Teapot

An Insider spills the beans on why Why broker research coverage of non-clients is collapsing (and worthless)

After a long City career Jason Streets has just joined paid for researcher Hardman and in a quite superb piece has spilled the beans on the collapse of traditional research and why the broker notes that are produced are just worthless pieces of marketing junk.Mr Streets does us all a service in laying out the hard facts which explains the death throes of broker research and its total lack of crredibility. Over to the man with the inside track.

Premaitha – does the company need to sack its PR too?

This is an utter shambles from AIM-listed Premaitha (NIPT). If you are going to go to the trouble and (shareholders’) expense of putting out an RNS to highlight some paid-for ramping research by Hardman, at least get the bloody RNS right! Tom Winnifrith has already had a furious rant that the company’s Broker, finnCap, should be sacked. Is the same true of the PR genii behind today’s abject efforts?

Premaitha Company chat - those 2 sets of forecasts and more: buy

The wider market is taking a bath and Premaitha (NIPT) shares are not immune to this now at 14.5p-15p. But there are also a couple of points which are company specific and in that vein we have had a detailed chat with the company on Friday.

Christmas-Stripper

No Problem Companies paying investment prostitutes for research and interviews BUT

Some folks think that I was wrong to call Louise Cooper an investment prostitute. I make no apologies. The silly cow painted herself as whiter than white, a Mother Theresa. The FACT is that she was more Princess Diana. She works for a company that takes cash from companies to interview them, then gives soft interviews without declaring the payments. That is investment prostitution and is WRONG. However...

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|